Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
March 2025
Belimumab efficacy in mucocutaneous lupus erythematosus: a large post-hoc analysis from five phase III clinical trials
Rheumatol, 2025. Epub ahead of print. DOI: 10.1093/rheumatology/keaf145
Grosso et al. conducted a post-hoc analysis of five phase III trials, including 3086 patients, to evaluate the efficacy of belimumab in improving mucocutaneous manifestations of SLE. The results demonstrated that belimumab significantly improved disease activity as measured by the mcBILAG and mcSLEDAI-2K indices compared with placebo and reduced flare rates in patients with high disease activity and serological positivity.
Keywords:
April 2024
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials
Ann Rheum Dis 2024 DOI 10.1136/ard-2023-225445 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38569851/
Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling.
February 2024
Evaluation of RNase Therapy in Systemic Lupus Erythematosus: A Randomised Phase 2a Clinical Trial of RSLV-132
Lupus Sci Med. 2024;11:e001113 DOI 10.1136/lupus-2023-001113
Treatment with RSLV-132 was associated with lower rates of SAEs than placebo, although RSLV-132 therapy was not associated with a significant improvement in the mean CLASI score relative to placebo. However, results suggest that further evaluations of RSLV-132 in SLE should be undertaken with patients with more active disease who are most likely to benefit from RNase therapy.
January 2024
Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2023; DOI: 10.1136/ard-2023-224854
This Phase 2 trial demonstrated the efficacy and acceptable safety profile of telitacicept in patients with SLE. The safety profile of telitacicept was comparable with that observed in clinical trials of other B cell-targeting agents.
Keywords:
December 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Arthritis Rheumatol. 2022. Epub ahead of print doi: 10.1002/art.42391
Phase II trial results of deucravacitinib support the potential benefits of TYK2 inhibition in SLE.
Keywords:
May 2022
Race, Ethnicity, and Disparities in Risk of End-organ Lupus Manifestations Following SLE Diagnosis in a Multiethnic Cohort
Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24892
California Lupus Epidemiology Study (CLUES) finds heightened risks of developing renal, haematologic, and multiorgan disease following SLE diagnosis among Hispanic and Asian patients with SLE.
Keywords:
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study Over a 41+ Year Period
Rheumatology (Oxford). 2022 Epub ahead of print
Retrospective observational study over a 41-year period finds complete remission (CR) in SLE to be associated with Caucasian race, older age at diagnosis, absence of renal involvement and absence of antiphospholipid syndrome.